Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing

NICE guideline
Draft for consultation, July 2018

This guideline sets out an antimicrobial prescribing strategy for managing and preventing an acute exacerbation of bronchiectasis (non-cystic fibrosis). It aims to optimise antibiotic use and reduce antibiotic resistance.

See a 3-page visual summary of the recommendations, including tables to support prescribing decisions.

Who is it for?

- Health professionals
- People with bronchiectasis, their families and carers

The guideline contains:

- the draft recommendations
- rationales explaining why the committee made their recommendations.

Information about how the guideline was developed is on the guideline’s page on the NICE website. This includes the full evidence review, details of the committee and any declarations of interest.
Recommendations

1.1 Managing an acute exacerbation of bronchiectasis
(non-cystic fibrosis)

1.1.1 Be aware that an acute exacerbation of bronchiectasis is a sustained worsening of symptoms from a person’s stable state.

To find out why the committee made the recommendations on awareness of acute exacerbation of bronchiectasis, see the rationales.

Treatment

1.1.2 Obtain a sputum sample from people with an acute exacerbation of bronchiectasis and send for culture and susceptibility testing.

1.1.3 Consider an antibiotic (see the recommendations on choice of antibiotic) for people with an acute exacerbation of bronchiectasis taking account of:

- the limited evidence base for antibiotics
- the number and severity of symptoms
- previous exacerbation and hospital admission history, and the risk of developing complications
- previous sputum culture and susceptibility results.

1.1.4 When results of sputum culture and susceptibility testing are available:

- review the choice of antibiotic, and
- only change the antibiotic according to susceptibility results if bacteria are resistant and symptoms are not already improving (using a narrow spectrum antibiotic wherever possible).

1.1.5 When an antibiotic prescription is given, give advice about:

- possible adverse effects of the antibiotic, particularly diarrhoea
1. seeking medical help if symptoms worsen rapidly or significantly at any time, or the person becomes systemically very unwell.

To find out why the committee made the recommendations on treatment of an acute exacerbation see the rationales.

**Reassessment**

1.1.6 Reassess the person if symptoms worsen rapidly or significantly at any time, taking account of:

- other possible diagnoses, such as pneumonia
- any symptoms or signs suggesting a more serious illness or condition, such as cardiorespiratory failure or sepsis
- previous antibiotic use which may have led to resistant bacteria.

To find out why the committee made the recommendations on reassessment, see the rationales.

**Referral and seeking specialist advice**

1.1.7 Refer people with an acute exacerbation of bronchiectasis to hospital if they have:

- cardiorespiratory failure, or
- a severe systemic infection, or
- any of the high risk criteria for severe illness or death from the NICE guideline on sepsis.

1.1.8 Seek specialist advice for an acute exacerbation of bronchiectasis if the person:

- has symptoms that are not improving with repeated courses of antibiotic treatment
- has bacteria that are resistant to oral antibiotics
- cannot take oral medicines (to explore locally available options for giving intravenous antibiotics at home or in the community, rather than in hospital, where this is appropriate).
To find out why the committee made the recommendations on referral and seeking specialist advice, see the rationales.

1.2 Choice of antibiotic for treating an acute exacerbation of bronchiectasis

1.2.1 When prescribing antibiotic treatment for an acute exacerbation of bronchiectasis:

- follow table 1 for adults aged 18 years and over
- follow table 2 for children and young people under 18 years.

1.2.2 Give oral antibiotics first line if the person can take oral medicines, and the severity of their condition does not require intravenous antibiotics.

1.2.3 Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible.

Table 1. Antibiotics for adults aged 18 years and over

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and course length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin</td>
<td>500 mg three times a day for 7 days then review</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>500 mg twice a day for 7 days then review</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>500 mg four times a day for 7 days then review</td>
</tr>
<tr>
<td>Doxycycline</td>
<td>200 mg on first day, then 100 mg once a day for a 7-day course in total then review</td>
</tr>
</tbody>
</table>

Second choice oral antibiotics if severely unwell or higher risk of certain pathogens (guided by susceptibilities when available)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and course length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amoxicillin high-dose (if severe and colonised with <em>Haemophilus influenzae</em> [beta-lactamase negative])</td>
<td>1 g three times a day or 3 g twice a day for 7 days then review</td>
</tr>
<tr>
<td>Co-amoxiclav (if severe, and not colonised with <em>Pseudomonas aeruginosa</em>)</td>
<td>500/125 mg three times a day for 7 days then review</td>
</tr>
<tr>
<td>Ciprofloxacin (if colonised with <em>Pseudomonas aeruginosa</em>; higher dose if severe)</td>
<td>500 mg or 750 mg twice a day for 7 days then review</td>
</tr>
</tbody>
</table>

First choice intravenous antibiotics (if unable to take oral antibiotics or...
severely unwell; guided by specialist advice and susceptibilities when available)\(^5\)

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and course length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftiraxone (not if colonised with <em>Pseudomonas aeruginosa</em>)</td>
<td>2 g once a day</td>
</tr>
<tr>
<td>Co-trimoxazole (not if colonised with <em>Pseudomonas aeruginosa</em>)(^6)</td>
<td>960 mg to 1,440 mg twice a day</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>2 g three times a day</td>
</tr>
<tr>
<td>Piperacillin with tazobactam</td>
<td>4.5 g three times a day, increased if necessary to 4.5 g four times a day</td>
</tr>
<tr>
<td>Ciprofloxacin</td>
<td>400 mg twice or three times a day</td>
</tr>
<tr>
<td>Co-amoxiclav</td>
<td>1.2 g three times a day</td>
</tr>
</tbody>
</table>

**Second choice intravenous antibiotics or combined therapy**
Consult local microbiologist; guided by susceptibilities

\(^1\)See BNF for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breast-feeding.

\(^2\)Empirical treatment or guided by most recent sputum culture and susceptibility.

\(^3\)Amoxicillin or erythromycin are the preferred choices in women who are pregnant.

\(^4\)Review treatment after 7 days and either stop the antibiotic if clinically stable or continue for a further 7 days as appropriate.

\(^5\)Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible for a total antibiotic course of 7 to 14 days.

\(^6\)Co-trimoxazole should only be considered for use in acute exacerbations of bronchiectasis when there is bacteriological evidence of sensitivity and good reason to prefer this combination to a single antibiotic (BNF, June 2018).

### Table 2. Antibiotics for children and young people under 18 years

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and course length</th>
</tr>
</thead>
</table>
| Amoxicillin | 1 to 11 months, 125 mg three times a day for 7 days then review\(^5\)  
              | 1 to 4 years, 250 mg three times a day for 7 days then review\(^5\)  
              | 5 to 17 years, 500 mg three times a day for 7 days then review\(^5\) |
| Clarithromycin | 1 month to 11 years:  
                    | Under 8 kg, 7.5 mg/kg twice a day for 7 days then review\(^5\)  
                    | 8 to 11 kg, 62.5 mg twice a day for 7 days then review\(^5\)  
                    | 12 to 19 kg, 125 mg twice a day for 7 days then review\(^5\)  
                    | 20 to 29 kg, 187.5 mg twice a day for 7 days then review\(^5\)  
<pre><code>                | 30 to 40 kg, 250 mg twice a day for 7 days then review\(^5\) |
</code></pre>
<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Erythromycin</strong></td>
<td>1 month to 1 year, 125 mg four times a day or 250 mg twice a day for 7 days then review; 2 to 7 years, 250 mg four times a day or 500 mg twice a day for 7 days then review; 8 to 17 years, 250 mg to 500 mg four times a day or 500 mg to 1,000 mg twice a day for 7 days then review</td>
</tr>
<tr>
<td><strong>Doxycycline</strong></td>
<td>12 to 17 years, 200 mg on first day, then 100 mg once a day for a 7-day course in total then review</td>
</tr>
<tr>
<td><strong>Second choice oral antibiotics if severely unwell or higher risk of certain pathogens (guided by susceptibilities when available)</strong></td>
<td></td>
</tr>
<tr>
<td>Amoxicillin high-dose (if severe and colonised with <em>Haemophilus influenzae</em> [beta-lactamase negative])</td>
<td>1 month to 11 years, 30 mg/kg (maximum 1g per dose) three times a day for 7 days then review; 12 to 17 years, 1 g three times a day for 7 days then review</td>
</tr>
<tr>
<td>Co-amoxiclav (if severe and not colonised with <em>Pseudomonas aeruginosa</em>)</td>
<td>1 to 11 months, 0.25 ml/kg of 125/31 suspension three times a day for 7 days then review; 1 to 5 years, 5 ml of 125/31 suspension three times a day or 0.25 ml/kg of 125/31 suspension three times a day for 7 days then review; 6 to 11 years, 5 ml of 250/62 suspension three times a day or 0.15 ml/kg of 250/62 suspension three times a day for 7 days then review; 12 to 17 years, 250/125 mg three times a day or 500/125 mg three times a day for 7 days then review</td>
</tr>
<tr>
<td>Ciprofloxacin (on specialist advice if colonised with <em>Pseudomonas aeruginosa</em>; higher dose if severe)</td>
<td>1 to 11 years, 20 mg/kg twice daily (maximum 750 mg per dose) for 7 days then review; 12 to 17 years, 500 mg or 750 mg twice a day for 7 days then review</td>
</tr>
<tr>
<td><strong>First choice intravenous antibiotics (if unable to take oral antibiotics or severely unwell; guided by specialist advice and susceptibilities when available)</strong></td>
<td></td>
</tr>
<tr>
<td>Ceftriaxone (not if colonised with <em>Pseudomonas aeruginosa</em>)</td>
<td>1 month to 11 years (up to 50 kg), 50 to 80 mg/kg once a day (maximum 4 g per day); 9 to 11 years (50 kg and above), 1 to 2 g once a day; 12 to 17 years, 1 to 2 g once a day</td>
</tr>
<tr>
<td>Co-trimoxazole (not if colonised with <em>Pseudomonas aeruginosa</em>)</td>
<td>6 weeks to 17 years, 18 mg/kg to 27 mg/kg twice a day (maximum 1440 mg per dose)</td>
</tr>
<tr>
<td>Ceftazidime</td>
<td>From 1 month, 25 to 50 mg/kg three times a day (maximum 6 g per day)</td>
</tr>
<tr>
<td>Piperacillin with tazobactam</td>
<td>1 month to 11 years, 90 mg/kg three or four times</td>
</tr>
</tbody>
</table>
a day (maximum per dose 4.5 g four times a day)
12 to 17 years, 4.5 g three times a day, increased
if necessary to 4.5 g four times a day

Ciprofloxacin
1 to 11 years, 10 mg/kg three times a day
(maximum 400 mg per dose)
12 to 17 years, 400 mg twice or three times a day

Co-amoxiclav
1 to 2 months, 30 mg/kg twice a day
3 months to 17 years, 30 mg/kg three times a day
(maximum 1.2 g three times a day)

Second choice intravenous antibiotic or combined therapy
Consult local microbiologist; guided by susceptibilities

1See BNF for children for appropriate use and dosing in specific populations, for example hepatic impairment and renal impairment.
2The age bands apply to children of average size and, in practice, the prescriber will use the age bands in conjunction with other factors such as the severity of the condition and the child’s size in relation to the average size of children of the same age.
3Empirical treatment or guided by most recent sputum culture and susceptibility.
4Amoxicillin or erythromycin are the preferred choices in young women who are pregnant.
5Review treatment after 7 days and either stop the antibiotic if clinically stable or continue for a further 7 days as appropriate.
6Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible for a total antibiotic course of 7 to 14 days.
7Co-trimoxazole should only be considered for use in acute exacerbations of bronchiectasis when there is bacteriological evidence of sensitivity and good reason to prefer this combination to a single antibiotic (BNF for children, June 2018).

1 To find out why the committee made the recommendations on choice and
duration of antibiotics for managing an acute exacerbation, see the rationales.
1.3 Preventing acute exacerbations of bronchiectasis (non-cystic fibrosis)

1.3.1 Do not routinely offer antibiotic prophylaxis to prevent acute exacerbations of bronchiectasis. Give advice about seeking medical help if symptoms of an acute exacerbation develop.

1.3.2 Only consider antibiotic prophylaxis (see the recommendations on choice of antibiotic) for adults with repeated acute exacerbations of bronchiectasis, taking account of evidence that antibiotics can:

- reduce exacerbations
- increase antimicrobial resistance
- cause adverse effects, particularly diarrhoea.

1.3.3 Before antibiotic prophylaxis is given, give advice about:

- the risk of antimicrobial resistance with long-term antibiotics, which may mean fewer effective antibiotics for future exacerbations
- possible adverse effects of long-term antibiotics, particularly diarrhoea, but also less common cardiac events with macrolide antibiotics
- possible interactions of macrolide antibiotics with other medicines
- returning for review after 3 months, or other agreed time.
1.3.4 When prescribing antibiotics to prevent acute exacerbations of bronchiectasis follow table 3 for adults aged 18 years and over.

1.3.5 Do not offer nebulised dornase alfa to prevent acute exacerbations of bronchiectasis.

1.3.6 Do not offer inhaled corticosteroids (with or without a long-acting beta2 agonist) for the sole purpose of preventing acute exacerbations of bronchiectasis.

To find out why the committee made the recommendations on preventing acute exacerbations of bronchiectasis, see the rationales.

1.4 Choice of antibiotic for preventing acute exacerbations

Table 3. Antibiotic prophylaxis for adults aged 18 years and over

<table>
<thead>
<tr>
<th>Antibiotic</th>
<th>Dosage and course length</th>
</tr>
</thead>
<tbody>
<tr>
<td>Azithromycin</td>
<td>500 mg three times a week or 250 mg daily</td>
</tr>
<tr>
<td>Clarithromycin</td>
<td>250 mg twice day</td>
</tr>
<tr>
<td>Erythromycin</td>
<td>500 mg twice a day</td>
</tr>
</tbody>
</table>

1 See **BNF** for appropriate use and dosing in specific populations, for example, hepatic impairment, renal impairment, pregnancy and breast-feeding.

2 Choose antibiotics according to recent sputum culture and susceptibility results where possible. Select a different antibiotic for prophylaxis if treating an acute exacerbation of bronchiectasis.

3 Doses given are by mouth using immediate release medicines, unless otherwise stated.

4 Erythromycin is the preferred choice in women who are pregnant.

To find out why the committee made the recommendations on choice of antibiotics for preventing acute exacerbations of bronchiectasis, see the rationales.
Terms used in this guideline

**Acute exacerbation of bronchiectasis**

An acute exacerbation of bronchiectasis is characterised by an acute deterioration of normal symptoms and signs usually over several days. It presents with a worsening cough (with increased sputum volume, viscosity, or purulence) with or without increased wheeze, breathlessness or haemoptysis; and/or fever or pleurisy. The presence of mucopurulent or purulent sputum alone without a deterioration in symptoms is not necessarily an acute exacerbation (NICE clinical knowledge summary – bronchiectasis, British Thoracic Society guideline on non-cystic fibrosis bronchiectasis 2010).

2 Rationales

**Awareness of acute exacerbation of bronchiectasis**

Recommendation 1.1.1

Why the committee made the recommendations

Based on experience, the committee agreed that an acute exacerbation is a sustained worsening of symptoms from a person's stable state. The committee agreed with the definition of an acute exacerbation in the BTS guideline on non-cystic fibrosis bronchiectasis 2010.

Return to the recommendations.

**Treatment**

Recommendations 1.1.2 to 1.1.5

Why the committee made the recommendations

Based on consensus, the committee agreed that although in the first instance antibiotic treatment will be empirical or based on the most recent sputum culture, a new sputum sample should be sent for culture to confirm susceptibility of the bacteria. The committee discussed that people with bronchiectasis are likely to have previous sputum samples, and because
pathogenic bacteria are reasonably static in this population, antibiotics that worked previously are a good starting point to treat new exacerbations. However, pathogenic bacteria can change and a new sputum sample should be sent for culture when people present with a new exacerbation of bronchiectasis.

The committee discussed the limited evidence base for antibiotics for treating an acute exacerbation of bronchiectasis. No evidence was found comparing antibiotics with placebo from systematic reviews or randomised controlled trials from the search, which went back to 2006. The committee was aware of UK guidelines that make recommendations for the antimicrobial treatment of acute exacerbations based on older, heterogeneous, head to head studies comparing different antibiotic regimens (often of intramuscular or intravenous antibiotics in hospitalised patients, which may not reflect current practice) and expert consensus. The committee agreed, based on their experience, that people with an acute exacerbation may benefit from antibiotic treatment, but this should be considered on an individual patient basis, based on the number and severity of their symptoms, their previous exacerbation and hospital admission history, their risk of developing complications, and previous sputum culture and susceptibility results. The committee noted that exacerbations could also be due to a viral infection or environmental factors rather than a bacterial infection.

Based on consensus, the committee agreed that when results of sputum cultures are available, if they suggest the bacteria are not susceptible, the person should be contacted to assess symptoms. However, the antibiotic should only be changed according to susceptibility results if symptoms are not already improving. In line with good antimicrobial stewardship, narrow spectrum antibiotics should be used wherever possible.

The committee agreed that when an antibiotic is given, people should be advised about possible adverse effects and also be given safety netting advice.

Return to the recommendations.
Reassessment

Recommendation 1.1.6

Why the committee made the recommendations

Based on experience, the committee agreed that, for safety netting, reassessment was needed if symptoms of the acute exacerbation worsen rapidly or significantly at any time.

Return to the recommendations.

Referral and seeking specialist advice

Recommendation 1.1.7 and 1.1.8

Why the committee made the recommendations

Based on experience, the committee agreed that, for safety netting, people with an acute exacerbation of bronchiectasis should be referred to hospital if they have cardiorespiratory failure, a severe systemic infection or suspected sepsis.

The committee discussed that some people with resistant bacteria (particularly *Pseudomonas aeruginosa*) may need intravenous antibiotics, particularly if they are not responding to several courses of oral antibiotics for the same episode, or if several sputum samples show resistance to oral antibiotics. The committee discussed that specialist advice should be sought for people needing intravenous antibiotics, to discuss local options for giving intravenous antibiotics at home or in the community, rather than in hospital, where this is appropriate for the individual.

The committee agreed, based on experience, that it may be necessary to use alternative antibiotics or combine antibiotics in the care of certain people who are severely unwell or have particular pathogens, but this should be done according to local policy on the advice of a microbiologist.

Return to the recommendations.
Choice of antibiotic for treating an acute exacerbation of bronchiectasis

Recommendations 1.2.1 to 1.2.3 and tables 1 and 2

Why the committee made the recommendations

Antibiotic choice

Very limited evidence was identified to guide the choice of antibiotic for treating an acute exacerbation of bronchiectasis.

Based on experience, common pathogens in acute exacerbations, the susceptibility of these to various classes of antibiotics, the risks of resistance, and good antimicrobial stewardship, the committee agreed the following antibiotic choices. Several oral and intravenous antibiotics were recommended to enable antibiotics to be selected based on the severity of illness and antibiotic susceptibilities from culture results when available.

First-choice oral antibiotics are:

- amoxicillin (a penicillin) at the usual dose of 500 mg three times a day for adults (with corresponding usual doses in children), which has good activity against common pathogens, such as *Streptococcus pneumoniae* and *Haemophilus influenzae*
- clarithromycin or erythromycin (macrolides; erythromycin is preferred in women who are pregnant) at usual doses
- doxycycline (a tetracycline; adults and young people over 12 years only) at the usual dose.

Second-choice oral antibiotics for people who are more severely unwell or are at higher risk of certain pathogens (guided by susceptibilities when available) are:

- high-dose amoxicillin (1 g three times a day or 3 g twice a day for adults; with corresponding doses in children), if severely ill and colonised with beta-lactamase negative *Haemophilus influenzae*
• **co-amoxiclav** (500/125 mg three times a day for adults; with corresponding doses in children), if severely ill and colonised with pathogens other than *Pseudomonas aeruginosa* (this broad-spectrum antibiotic combines a penicillin with a beta-lactamase inhibitor, making it active against beta-lactamase-producing bacteria that are resistant to amoxicillin alone)

• or **ciprofloxacin** (500 mg or 750 mg twice a day; with corresponding doses in children [only on specialist advice because quinolones are generally not recommended in children or young people who are growing], a quinolone which should be reserved for people colonised with *Pseudomonas aeruginosa* only.

First-choice **intravenous antibiotics** at usual doses for treating acute exacerbations in people who are severely unwell, not responding to or unable to take oral antibiotics (guided by specialist advice and susceptibilities when available) are:

• **ceftriaxone** (a third generation cephalosporin), which is suitable for people not colonised with *Pseudomonas aeruginosa*

• **co-trimoxazole** (trimethoprim plus a sulphonamide), which is suitable for people not colonised with *Pseudomonas aeruginosa*

• **ceftazidime** (a third generation cephalosporin)

• **piperacillin with tazobactam** (an antipseudomonal penicillin with a beta-lactamase inhibitor)

• **ciprofloxacin** (a quinolone)

• **co-amoxiclav** (a penicillin with a beta-lactamase inhibitor).

The committee discussed that some people with resistant bacteria (particularly *Pseudomonas aeruginosa*) may need intravenous antibiotics, particularly if they are not responding to several courses of oral antibiotics for the same episode, or if several sputum samples show resistance to oral antibiotics.

The committee discussed that specialist advice should be sought for people needing intravenous antibiotics, to discuss which antibiotics are suitable and...
the local options for giving intravenous antibiotics at home or in the community, rather than in hospital, where this is appropriate for the individual.

The committee agreed, based on experience, that it may be necessary to use alternative antibiotics or combine antibiotics in the care of certain people who are severely unwell or have particular pathogens, but this should be done according to local policy on the advice of a microbiologist.

The committee discussed evidence from a randomised controlled trial which showed that adding nebulised tobramycin to oral ciprofloxacin did not improve the resolution of exacerbation symptoms, and increased wheeze. The committee agreed that combining a nebulised antibiotic with an oral antibiotic for the treatment of an acute exacerbation added no additional benefit and should not be routinely offered.

**Antibiotic course length**

Very limited evidence was identified to guide the duration of antibiotics for treating an acute exacerbation of bronchiectasis. The 1 RCT identified, which compared a nebulised antibiotic plus an oral antibiotic with an oral antibiotic alone, used a 14-day course. However, the committee were aware of the [British Thoracic Society guideline on non-cystic fibrosis bronchiectasis 2010](https://www.brit-thoracic.org.uk/wp-content/uploads/2022/11/Non-Cystic-Fibrosis-Bronchiectasis-Guideline-2010.pdf) which includes older head to head studies comparing different oral, intravenous or intramuscular antibiotic regimens, which used 7-day, 10-day or 14-day courses.

Based on consensus, the committee agreed that the shortest course that is likely to be effective should be prescribed to reduce the risk of antimicrobial resistance and minimise the risk of adverse effects.

The committee agreed that a minimum of a 7-day course of all the recommended antibiotics was required to treat an acute exacerbation. At 7 days, treatment should be reviewed, and either stopped if the person is clinically stable or continued for a further 7 days as appropriate.
Oral antibiotics should be used first-line where possible, in line with the NICE guideline on antimicrobial stewardship. The committee discussed that some people with resistant bacteria (particularly *Pseudomonas aeruginosa*) may need intravenous antibiotics, particularly if they are not responding to several courses of oral antibiotics for the same episode, or if several sputum samples show resistance to oral antibiotics.

The committee agreed that the use of intravenous antibiotics should be reviewed by 48 hours (taking into account the person’s response to treatment and susceptibility results from sputum culture) and switched to oral treatment where possible. This aligns with the NICE guideline on antimicrobial stewardship and **Start smart – then focus**.

Return to the recommendations.

### Preventing acute exacerbations of bronchiectasis (non-cystic fibrosis) and choice of antibiotic

Recommendations 1.3.1 to 1.3.6 and table 3

#### Why the committee made the recommendations

**Prophylactic antibiotics**

The committee discussed the evidence for prophylactic antibiotics. Overall, antibiotics reduced exacerbation rates, hospitalisations and the number of people with an exacerbation. However, there was a significant increase in antibiotic resistance and adverse effects.

The majority of the studies were in populations who had experienced multiple exacerbations in the previous year and the committee thought the findings could not be generalised to everyone with bronchiectasis.

Based on evidence and experience, the committee agreed that all people should not routinely be offered antibiotic prophylaxis to prevent acute exacerbations, because of the risk/benefit balance in the overall population.

However, although routine antibiotic prophylaxis is not recommended, this
could be considered for adults with repeated exacerbations, where the benefits of prophylaxis may outweigh the risks.

The committee discussed that most evidence was found for oral macrolide antibiotics in adults, where they reduced exacerbation rates and the number of people with an exacerbation. However, they also increased antibiotic resistance and adverse effects. Nebulised or inhaled prophylactic antibiotics had no effect on exacerbations in adults. In 1 small trial of nebulised tobramycin, a non-significant increase in exacerbations, and adverse events such as dyspnoea, chest pain and wheeze were seen.

The majority of the studies were in populations who had experienced multiple exacerbations in the previous year. However, the populations had a variety of exacerbation histories with no clear benefit seen in a specific population. The committee felt it was, therefore, difficult to give a precise definition of ‘repeated exacerbations’. Clinical judgement would be needed to define this on an individualised patient basis, taking into account the frequency and severity of exacerbations, and the individualised risks and benefits of long-term antibiotics.

The limited evidence in children and young people found prophylactic oral macrolide antibiotics had no effect on exacerbations but increased antimicrobial resistance, and no recommendation for prophylaxis in children and young people was made.

The committee agreed that before antibiotic prophylaxis is given, people should be advised about the harms of long-term antibiotics. There is an increased risk of resistance with long-term antibiotics, which impacts at both a population and an individual level. People should be advised that this can mean fewer antibiotics may work for their exacerbations in the future. People should also be advised about possible common adverse effects, such as diarrhoea, but also about less common cardiac adverse events. They should also be advised about the potential for macrolide antibiotics, in particular, to interact with other medicines. The committee agreed that anyone being
offered antibiotic prophylaxis should return for a review after 3 months, or other agreed time.

The committee discussed that the evidence of benefit for antibiotic prophylaxis was with oral macrolides (which included azithromycin, clarithromycin, erythromycin and roxithromycin [not available in the UK]). They discussed that macrolides may have anti-inflammatory or intracellular effects which is why they may show benefit over other antimicrobials. Nebulised or inhaled antibiotics (not all of which are available in the UK) had no effect on exacerbations. However, the evidence base was limited with low patient numbers in all studies.

Based on the evidence, the committee recommended azithromycin (500 mg three times a week or 250 mg daily), clarithromycin 250 mg twice day or erythromycin 500 mg twice a day where antibiotic prophylaxis was considered appropriate. Nebulised or inhaled antibiotics were not recommended.

**Non-antimicrobial interventions**

Evidence showed that nebulised dornase alfa increased exacerbation rates in adults with bronchiectasis, and resulted in more people using antibiotics and steroids. Therefore the committee agreed that nebulised dornase alfa should not be offered to prevent acute exacerbations of bronchiectasis.

Evidence showed that inhaled corticosteroids (with or without a long-acting beta2 agonist) had no effect on acute exacerbations of bronchiectasis in adults. Based on experience, the committee also discussed the potential for adverse effects with inhaled corticosteroids. Therefore the committee agreed that inhaled corticosteroids should not be offered solely to prevent acute exacerbations.

Return to the recommendations.

See the full evidence review for more information.